4889.T
Renascience Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 1,135.00
−1.13%Jul 21, 2026, 22:32 UTC
Renascience Inc. has initiated a Phase 2 clinical trial of its PAI-1 inhibitor RS5614 for locally advanced non-small cell lung cancer.
Source:Jul 21, 2026, 06:43 UTC
Renascience announced the start of a Phase II physician-led trial of PAI-1 inhibitor RS5614 in combination with chemoradiotherapy and durvalumab for locally advanced non-small cell lung cancer, with first patient dosed on July 16, 2026.